Results 1 to 10 of about 81,586 (214)

Interim Positron Emission Tomography-Adapted Treatment Strategies for Classic Hodgkin Lymphoma: Insights From Korean Real-World Data. [PDF]

J Korean Med Sci
Byeon S, Kang KW, Kwak K, Yoo KH, Yoon SE, Kim WS, Kim SJ.   +6 more
europepmc   +1 more source

Coexistence of Mycosis Fungoides and Hodgkin Lymphoma in a Pediatric Patient: A Report of a Rare Case. [PDF]

Cureus
Cruz Medina CS, Barrientos Hernandez JA, Vargas Vargas VM, Escamilla López MI, Bernal ET.   +4 more
europepmc   +1 more source

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility. [PDF]

Medicina (Kaunas)
Candan O, Buyukkurkcu B, Karti S, Uzay A.   +3 more
europepmc   +1 more source

Mortality and major comorbidities in coeliac disease: implications for long-term care. [PDF]

Lancet Reg Health Am
Lenti MV, Corazza GR, Di Sabatino A.
europepmc   +1 more source

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma. [PDF]

Cancer
Tharmaseelan H, Jablonski J, Bühnen I, Fuchs M, Rosenbrock J, Eich HT, Ferdinandus J, Jaworek CP, Bröckelmann PJ, Borchmann P, Eichenauer DA.   +10 more
europepmc   +1 more source

<i>Erratum</i> to: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma". [PDF]

Haematologica
Lia K, Jørgensen RRK, Wikman P, Wold BL, Övergaard N, Fluge Ø, Fagerli UM, Bersvendsen H, Bø IB, Bhargava S, Molin D, Fosså A.   +11 more
europepmc   +1 more source

Global welfare burden of hematologic malignancies from 2015 to 2023. [PDF]

iScience
Zhou Y, Cai X, Zhao Y, Li D.
europepmc   +1 more source

Should bilateral (versus unilateral) bone marrow biopsies be routine in paediatric classical Hodgkin Lymphoma where PET-CT is unavailable? [PDF]

Afr J Lab Med
Kennedy SJ, Jonas MT, van Marle AC, du Plessis J.   +3 more
europepmc   +1 more source

Clinical characteristics and outcomes of Hodgkin Lymphoma: A single institution retrospective cohort study. [PDF]

PLoS One
Rjoop A, Al-Samama'h R, Al-Ullemat TS, Alshamali R, El-Dwakat B, Al-Saidi R, Abdalhakem N, Alsarhan S, Ajarmeh A.   +8 more
europepmc   +1 more source

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial. [PDF]

Blood Adv
Scheid C, Jablonski J, Kerkhoff A, Stelljes M, Trautmann-Grill K, Bornhäuser M, Tischer JM, von Bergwelt-Baildon M, Janson D, Ayuk F, Kröger N, Holtick U, Richardson T, von Tresckow B, Fuchs M, Borchmann P, Bröckelmann PJ.   +16 more
europepmc   +1 more source